Author:
Offersgaard Anna,Duarte Hernandez Carlos R.,Zhou Yuyong,Duan Zhe,Gammeltoft Karen Anbro,Hartmann Katrine T.,Fahnøe Ulrik,Marichal-Gallardo Pavel,Alzua Garazi Peña,Underwood Alexander P.,Sølund Christina,Weis Nina,Bonde Jesper Hansen,Christensen Jan P.,Pedersen Gabriel K.,Jensen Henrik Elvang,Holmbeck Kenn,Bukh Jens,Gottwein Judith Margarete
Publisher
Springer Science and Business Media LLC
Reference60 articles.
1. Carabelli, A. M. et al. SARS-CoV-2 variant biology immune escape transmission and fitness. Nat. Rev. Microbiol. 21, 162–177 (2023).
2. WHO. Initial Risk Evaluation of BA.2.86 and its sublineages, 21 November 2023. Accessed 2023 Dec 21. WHO. Available from: https://www.who.int/docs/default-source/coronaviruse/21112023_ba.2.86_ire.pdf?sfvrsn=8876def1_3 (2023).
3. Krammer, F. SARS-CoV-2 vaccines in development. Nature 586, 516–527 (2020).
4. Jara, A. et al. Effectiveness of an inactivated SARS-CoV-2 vaccine in Chile. N. Engl. J. Med. 385, 875–884 (2021).
5. Cohen, J. China’s vaccine gambit. Science 370, 1263–1267 (2020).